| abstract |
The present invention corresponds to a biomarker in which ACAA1, AP1M2, CGN, DDR1, EPS8L2, FASTKD1, GMIP, IKBKE, P2RX4, P4HB, PHKG2, PPFIBP2, PPP1R16A, RASSF7, RNF183, SIRT6, TJP3, EFEMP2, SOCS2, and DCN. It is related to the surprising discovery that they are differentially expressed in control samples when compared to samples of patients with endometrial cancer and are therefore useful for detecting endometrial cancer. In particular, these biomarkers have excellent sensitivity, specificity, and / or ability to separate affected individuals from uninfected individuals. In addition, the inventors have found that different expressions of these biomarkers in primary endometrial cancer tumor tissues are associated with their expression levels in uterine fluid samples when compared to control values. Thus, these biomarkers are potent in that they have been found to be differentially expressed in several different types of samples of affected individuals. |